Arrotex boosts respiratory portfolio to $263m with new Boehringer Ingelheim partnership

Arrotex Pharmaceuticals is today announcing a strategic partnership with Boehringer Ingelheim for the exclusive Australian reseller rights to respiratory brand Spiriva.

Used for the treatment of chronic obstructive pulmonary disease (COPD), the Spiriva brand currently has a market value of AUD 34 million, increasing Arrotex’ respiratory portfolio to AUD 263.5 million.

Following the 2019 merger of Apotex and Arrow Pharmaceuticals, the combined Arrotex entity now promotes GSK’s Seretide, Pavtide (Seretide authorised generic), Flixotide and Ventolin brands along with AstraZeneca’s respiratory brands Symbicort, Pulmicort, Omnaris, Alvesco, Bricanyl and Oxis.

Arrotex told Health Industry Hub that GSK, AstraZeneca and Boehringer Ingelheim will continue to promote these brands to GPs via their internal field forces. Arrotex’s extensive pharmacy sales team will promote the respiratory products to all community pharmacies.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our proven digital media solutions developed by industry for industry.

Lisa Golden, Arrotex Chief Commercial Officer said: “Strategic partnerships such as this new Boehringer Ingelheim arrangement, as well as existing collaborations with GSK and AstraZeneca, represent a unique element of the Apotex and Arrow offer to pharmacy.

“Through our strategic partnerships, Arrotex creates value for Australian community pharmacy, by offering access to brand product discounts that would otherwise be unavailable to our customers. This is an example of Arrotex’ unique approach to value creation for our customers who are operating in the competitive retail pharmacy market,” she said.

The partnership with Boehringer Ingelheim will take effect 10 February 2020 and Apotex and Arrow will soon contact pharmacies with details of commercial arrangements.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

You may also like Novartis’ new drug – an attractive option in AMD treatment